Four New Administrators on BIOQuébec's Board
BIOQuébec’s Board of Directors Enhances Its Support of the Strategic Development of Québec’s Biotechnology and Life Sciences Network
BROMONT (Québec) October 6, 2017 – Martin Godbout, President of BIOQuébec’s board of directors, has announced that effective immediately, Frank Béraud, Chief Executive Officer of Montréal InVivo, Maha Katabi, Partner, Private Equity at Sectoral Asset Management, Jean-Frédéric Lafontaine, Senior Manager, Government Relations at AstraZeneca Canada Inc., and Suzie Talbot, President and CEO of Diex Research, have been named to BIOQuébec’s board of directors as administrators.
“On behalf of myself and of BIOQuébec’s board of directors, I am very proud to welcome Maha, Suzie, Frank, and Jean-Frédéric to our team”, stated Mr. Godbout. “Their professional experience, wide range of skills, leadership, and in-depth knowledge of the issues facing our sector make them exceptional appointees. They will be important assets for our organization and our members.”
Frank Béraud was named Chief Executive Officer of Montréal InVivo in 2015 and he has close to 25 years of experience in the life sciences industry. Prior to joining Montréal InVivo in 2010 as Project Manager, he was BIOQuébec’s Director of Policies and Strategic Development. He was also director of marketing and business development of a small biotechnology firm. He holds a bachelor’s degree in biochemistry from Grenoble’s Université Joseph Fourier and an MBA from the Université du Québec à Montréal.
With 15 years of experience in private investment, Maha Katabi joined the Sectoral Asset Management team in 2008 before being promoted to partner in 2012. Previously, she had been Vice-President of Ventures West, a private Canadian venture capital firm with a total committed capital of over $700 million. Her responsibilities included managing investments in biotechnology across Canada and the U.S. She holds a bachelor’s degree in biology and a PhD in pharmacology from McGill University. She obtained her CFA title in 2011.
For nearly 10 years, Jean-Frédéric Lafontaine has been Senior Manager of Government Relations at AstraZeneza Canada Inc. President of the Fédération des chambres de commerce du Québec’s life sciences committee, he is also a member of the board of directors at both Héma-Québec and the NEOMEd Institute. He holds a bachelor’s degree in neurobiology from McGill University and a master’s degree in health law from the Université de Sherbrooke.
Suzie Talbot has over 20 years of experience in clinical research and founded DIEX Research with her associate Jean-François Lessard in 2006. She has held the position of President and CEO since its very inception. She was also Copresident of Estrie’s SAGE-Innovation, a community of more than 40 healthcare companies fostering the development of innovations and of structuring projects. She holds a bachelor’s degree in nursing from the Université de Montréal and an MBA from the Université de Sherbrooke.
BIOQuébec’s board of directors includes members from all levels of the life sciences innovation chain, from discovery to marketing, which allows it to provide strong and relevant support for BIOQuébec’s strategic development.
BIOQuébec is committed to supporting the growth of Québec’s biotechnology and life sciences industry which creates wealth and specialized jobs, is focused on innovation and marketing, and is dedicated to improving everyone’s health and quality of life. For more information, go to www.bioquebec.com
- (30) -
Anie Perrault, Executive Manager, BIOQuébec